On Jul 1, 2021 OBVIOHEALTH closed a Series B round and raised $31,000,000 from AT Capital Group, Dedalus Group, Novotech, SPRIM, featuring lead investors Dedalus Group, Novotech.

About the company: OBVIOHEALTH is located in Singapore, Asia. “ObvioHealth conducts virtual clinical trials that deliver better data. Our mobile app allows for a decentralized trial design so subjects can use their smartphones to participate in research from the comforts of their homes.” ObvioHealth has conducted 42 studies in 28 countries with more than 25,000 participants.

Company website: obviohealth.com/